Immatics
Update in progressIMTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immatics N.V. is a clinical-stage biopharmaceutical company developing T cell–redirecting immunotherapies for cancer in the United States. It targets solid tumors with two modalities: adoptive cell therapies (ACT) and TCR bispecifics. Its pipeline includes Anzu-cel (IMA203) PRAME cell therapy (Phase 2), IMA203CD8 (Phase 1), IMA204 (Phase 1), Anzu-cel with mRNA-4203 (Phase 1), and TCR bispecifics IMA401/IMA402 (Phase 1a). Partnerships with MD Anderson, Celgene, and Genmab. Headquartered in Tübingen, Germany.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- -0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationGermany
- CEODr. Harpreet Singh Ph.D.
- Employees589
- Websitewww.immatics.com
Identifiers
- ISINNL0015285941
- FIGIBBG00VTL2H76
- CIK0001809196